GO:0070489 T cell aggregation: Adhesion, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070489 T cell aggregation is defined as the adhesion of one T cell to one or more other T cells via adhesion molecules.
• Homotypic T cell aggregation is a measurable, activation-linked behavior of T cell lines and primary T cells, and can be triggered by chemical exposure such as bifenthrin.
• Aggregation of T cell-redirecting bispecific antibodies can cause target-independent immune-cell activation, a critical safety issue in immunotherapy development.
• T cell aggregation and infiltration are mechanistically linked to neurodegeneration in tauopathy models, where microglia mediate T cell entry into the brain.
• Spatially resolved tumor atlases identify lymphocyte-aggregated regions in gastric cancer, linking T cell aggregation to cancer immunity and tertiary lymphoid structure biology [3,8].
• Engineered aggregation strategies, such as ferritin aggregation cell engagers, are being developed to enhance CAR T avidity against refractory leukemias.
Description
T cell aggregation (GO:0070489) is a biological process defined as the adhesion of one T cell to one or more other T cells via adhesion molecules. This process is distinct from T cell activation, proliferation, or migration, although it is often observed as a downstream consequence of receptor engagement and cytoskeletal reorganization during immune responses. In experimental immunology, homotypic aggregation assays have long been used as a rapid readout of T cell activation status and adhesion molecule function. The term captures a fundamental cell-cell interaction that shapes immune synapse formation, lymphoid tissue organization, and pathological T cell infiltration [1,3]. Understanding T cell aggregation matters because it sits at the intersection of basic immunology and translational medicine. In cancer, aggregated T cells contribute to tertiary lymphoid structures and lymphocyte-aggregated regions that correlate with improved immune surveillance [3,8]. In neurodegeneration, microglia-mediated T cell infiltration and aggregation drive tauopathy-associated pathology. In biotherapeutics, unwanted aggregation of T cell-redirecting bispecific antibodies can trigger target-independent immune-cell activation, raising safety concerns for clinical development. Conversely, engineered aggregation approaches such as ferritin aggregation cell engagers are being explored to boost CAR T avidity against refractory leukemias. This article synthesizes authoritative QuickGO annotation data with verified PubMed literature to provide a research-grade overview of GO:0070489. It covers the definition, mechanistic stages, key genes and adhesion molecules, disease relevance, and the CRISPR-based experimental models available to study T cell aggregation in a controlled, publication-ready manner [1,2,3,4,6,7,8].
T cell aggregation At A Glance
| GO ID | GO:0070489 |
|---|---|
| GO term | T cell aggregation |
| Ontology | biological_process |
| Synonym | T-cell aggregation; T lymphocyte aggregation; T-lymphocyte aggregation |
| Definition | The adhesion of one T cell to one or more other T cells via adhesion molecules |
| Major function | Homotypic T cell adhesion underlying immune synapse formation, lymphoid organization, and pathological infiltration [1,3,4] |
| Experimental readout | Formation of T cell clusters in suspension, often quantified by microscopy or flow cytometry |
| Disease relevance | Tauopathy neurodegeneration, gastric cancer immunity, leukemia immunotherapy safety and efficacy [1,2,3,7] |
| Therapeutic angle | Aggregation can be undesirable (bispecific antibody aggregates) or engineered for benefit (ferritin aggregation cell engagers) [2,7] |
What Is GO:0070489?
GO:0070489 T cell aggregation is the biological process in which one T cell adheres to one or more other T cells through adhesion molecules. The term is synonymous with T-cell aggregation, T lymphocyte aggregation, and T-lymphocyte aggregation. It describes a homotypic cell-cell adhesion event rather than a signaling or differentiation process, although it is frequently coupled to activation-induced changes in adhesion molecule expression and avidity [4,6]. The process can be measured experimentally as the formation of multicellular T cell clusters in suspension culture, and it depends on the functional engagement of surface receptors and their ligands.
Why Is T cell aggregation Important in Cell Biology?
T cell aggregation is important because it is a direct, measurable manifestation of T cell adhesion biology that influences immune synapse formation, lymphoid tissue architecture, and the balance between protective immunity and immunopathology [1,3,4]. In cancer, lymphocyte-aggregated regions and tertiary lymphoid structures are associated with active cancer-immunity cycles and are being mapped at spatial resolution to guide immunotherapy [3,8]. In neurodegeneration, microglia-mediated T cell infiltration and aggregation contribute to tauopathy progression, identifying T cell adhesion as a potential therapeutic node. In biopharmaceutical development, aggregation of T cell-redirecting bispecific antibodies can cause target-independent immune-cell activation, a safety liability that must be engineered out. Conversely, deliberate aggregation strategies such as ferritin aggregation cell engagers are being harnessed to improve CAR T avidity against refractory leukemias. Together, these findings establish GO:0070489 as a process with broad relevance across oncology, neuroscience, and therapeutic engineering.
• Provides a mechanistic basis for homotypic T cell adhesion during immune activation and immune synapse formation.
• Serves as a rapid experimental readout of T cell activation and adhesion molecule function in vitro.
• Contributes to microglia-mediated T cell infiltration and neurodegeneration in tauopathy models.
• Correlates with lymphocyte-aggregated regions and tertiary lymphoid structures in gastric cancer [3,8].
• Underlies a safety liability when T cell-redirecting bispecific antibodies aggregate and cause target-independent activation.
• Can be engineered for therapeutic benefit using ferritin aggregation cell engagers to enhance CAR T avidity.
• Is relevant to the quantitative annotation and specificity analysis of T cell repertoires in immune monitoring.
• Links cell surface adhesion biology to spatial tumor immunology and immunotherapy response prediction.
• Offers a tractable phenotype for CRISPR screens targeting adhesion and cytoskeletal regulators.
• Bridges basic immunology, neuroinflammation, and biotherapeutic engineering in a single GO term [1,2,7].
What Happens During T cell aggregation?
Initiation by adhesion molecule engagement
In simple terms: T cells stick to each other when adhesion molecules on their surfaces lock together.
T cell aggregation begins when adhesion molecules on the surface of one T cell engage counter-receptors on another T cell, forming homotypic contacts. This process is distinct from T cell-APC interactions and is driven by the same families of adhesion receptors that mediate immune synapse formation. CD28/CTLA-4 receptor structure and binding stoichiometry studies have shown that receptor aggregation during T-cell activation is a regulated event, providing a conceptual framework for how surface receptor clustering can drive cell-cell adhesion. The QuickGO definition explicitly restricts GO:0070489 to adhesion via adhesion molecules, emphasizing that this is a receptor-mediated process rather than passive clumping.
Activation-induced cytoskeletal remodeling
In simple terms: Inside the T cell, the skeleton rearranges to push the cells together and hold them in contact.
Following receptor engagement, T cells undergo cytoskeletal remodeling that stabilizes cell-cell contacts and promotes cluster formation. Chemical exposure studies using human T-cell lines demonstrated that bifenthrin activates homotypic aggregation, indicating that environmental and pharmacological stimuli can trigger the cytoskeletal and adhesion changes required for aggregation. This activation-linked aggregation is measurable as the formation of multicellular clusters in suspension culture, and it depends on intact adhesion molecule function.
Cluster formation and stabilization
In simple terms: Individual T cells gather into stable clusters that can be seen under a microscope.
Once initial contacts are established, T cells form multicellular clusters that can be quantified by microscopy or flow cytometry. These clusters represent the observable endpoint of GO:0070489 and are used experimentally as a proxy for adhesion molecule activity. In pathological settings, similar aggregation behavior contributes to T cell infiltration and accumulation in tissues, as seen in microglia-mediated T cell infiltration in tauopathy. The stability of these clusters depends on continued adhesion molecule engagement and is sensitive to perturbations of the underlying signaling pathways [4,6].
Pathological and therapeutic aggregation contexts
In simple terms: Aggregation can be harmful in some diseases and useful in engineered therapies.
In disease, T cell aggregation is linked to neurodegeneration, where microglia-mediated T cell infiltration drives tauopathy pathology, and to cancer immunity, where lymphocyte-aggregated regions and tertiary lymphoid structures are characterized in spatially resolved tumor atlases [3,8]. In biotherapeutics, aggregation of T cell-redirecting bispecific antibodies can cause target-independent immune-cell activation, a critical safety concern. Conversely, ferritin aggregation cell engagers have been engineered to promote controlled aggregation and enhance CAR T avidity against refractory leukemias. These contrasting contexts illustrate why precise experimental control of GO:0070489 is essential.
Quantitative annotation and repertoire context
In simple terms: Researchers use computational tools to describe which T cells are involved and how specific they are.
Quantitative annotations of T cell repertoire specificity provide a computational framework for interpreting which T cell clones participate in aggregation events and how specific their recognition is. Such annotations complement experimental aggregation assays by linking clonal identity to functional behavior. In spatially resolved tumor atlases, lymphocyte-aggregated regions can be mapped and correlated with repertoire features, connecting GO:0070489 to broader immune monitoring efforts [3,5].
Key Genes Involved in GO:0070489 T cell aggregation
The following genes and proteins are experimentally and conceptually linked to T cell aggregation (GO:0070489) based on the verified literature, including adhesion receptors, co-stimulatory molecules, and aggregation-associated effectors.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CD28 | Co-stimulatory receptor whose aggregation during T-cell activation is structurally and stoichiometrically characterized | Model for receptor clustering and adhesion-dependent T cell activation |
| CTLA-4 | Inhibitory receptor that binds CD28 ligands and participates in receptor aggregation during T-cell activation | Target for checkpoint blockade and aggregation studies |
| CD3 | T cell receptor complex component required for activation-induced aggregation responses | Core marker for T cell identity in aggregation assays |
| ITGAL (LFA-1) | Integrin mediating homotypic T cell adhesion and cluster stabilization | Candidate for CRISPR KO to test adhesion dependence |
| ITGB2 (CD18) | Integrin beta chain partnering with LFA-1 in T cell adhesion | Loss-of-function models for aggregation defects |
| ICAM1 | Adhesion ligand that can support T cell-T cell contacts in inflammatory contexts | Relevant to microglia-T cell interaction in tauopathy |
| CD2 | Adhesion molecule contributing to T cell conjugate formation | Target for aggregation perturbation studies |
| CD58 | Ligand for CD2 involved in cell-cell adhesion | Model for adhesion pair disruption |
| PTPRC (CD45) | Phosphatase regulating T cell receptor signaling and activation-dependent adhesion | Modifier of aggregation responses |
| ACTB | Cytoskeletal actin required for cluster formation and stabilization | Cytoskeletal perturbation model |
| ACTG1 | Actin isoform contributing to cytoskeletal remodeling during aggregation | Redundancy studies with ACTB |
| RAC1 | Small GTPase regulating actin dynamics downstream of adhesion receptors | Candidate for aggregation rescue experiments |
| CDC42 | Small GTPase controlling cytoskeletal reorganization in T cells | Loss-of-function aggregation studies |
| FERMT3 | Adapter linking integrins to the cytoskeleton in leukocytes | Integrin activation model |
| VAV1 | Guanine nucleotide exchange factor downstream of TCR and integrins | Signaling node for aggregation |
| ZAP70 | Kinase transducing TCR signals that lead to activation-induced adhesion | Kinase-dead and KO models |
| LCK | Src-family kinase initiating TCR signaling and downstream adhesion changes | Upstream regulator of aggregation |
How Is T cell aggregation Regulated?
T cell aggregation is regulated at multiple levels, including receptor clustering, intracellular signaling, and cytoskeletal dynamics. CD28/CTLA-4 receptor aggregation during T-cell activation is a regulated structural event with defined binding stoichiometry, indicating that co-stimulatory receptor organization controls the threshold for adhesion-dependent responses. Downstream of receptor engagement, kinases such as LCK and ZAP70 and guanine nucleotide exchange factors such as VAV1 transduce signals that remodel the actin cytoskeleton through RAC1 and CDC42, enabling cluster formation and stabilization. Environmental and pharmacological stimuli, such as bifenthrin, can activate homotypic aggregation in human T-cell lines, demonstrating that the process is responsive to external cues. In pathological contexts, microglia-mediated signals promote T cell infiltration and aggregation in tauopathy, indicating that non-T cell populations can regulate this process in trans. Finally, aggregation of T cell-redirecting bispecific antibodies can trigger target-independent immune-cell activation, showing that the physical state of therapeutic molecules can regulate T cell aggregation independently of antigen specificity.
T cell aggregation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CD28 | T cell activation and co-stimulation in autoimmunity and cancer | Knockout and point-mutation T cell lines |
| CTLA-4 | Immune checkpoint regulation and cancer immunotherapy | Knock-in reporter and KO models |
| ITGAL | Leukocyte adhesion deficiency and inflammatory disease | Knockout primary T cells and cell lines |
| ICAM1 | Neuroinflammation and tauopathy-associated T cell infiltration | Microglia-T cell co-culture models |
| CD3 | T cell engager therapy and leukemia [2,7] | CAR T and bispecific antibody assays [2,7] |
T cell aggregation in tauopathy neurodegeneration
Microglia-mediated T cell infiltration drives neurodegeneration in tauopathy, establishing a direct link between T cell accumulation in the brain and neuronal loss. In this context, T cell aggregation and infiltration represent a pathological process in which T cells enter the central nervous system and contribute to disease progression. This finding positions GO:0070489 as a potential therapeutic target in neurodegenerative disease, where blocking T cell adhesion or infiltration could attenuate tauopathy-associated damage.
T cell aggregation and cancer immunity
Spatially resolved atlases of gastric cancer have characterized lymphocyte-aggregated regions, linking T cell aggregation to tumor immune architecture. T cell exhaustion initiates tertiary lymphoid structures and turbocharges the cancer-immunity cycle, connecting aggregation-related lymphoid organization to anti-tumor immunity. These studies suggest that T cell aggregation within tumors is not merely a histological feature but an active contributor to immune surveillance and potential response to immunotherapy [3,8].
Aggregation in T cell-redirecting bispecific antibody therapy
Aggregates of T cell-redirecting bispecific antibodies can cause target-independent immune-cell activation, a safety liability in clinical development. This form of aggregation is distinct from cellular homotypic aggregation but directly impacts T cell behavior and activation state. Understanding and controlling aggregation at the protein level is therefore essential for the safe design of T cell engagers.
Engineered aggregation for CAR T avidity
Ferritin aggregation cell engagers have been developed for CAR T avidity engineering against refractory leukemias, demonstrating that controlled aggregation can be harnessed therapeutically. This approach exploits the principles of multivalent engagement and clustering to enhance T cell-target interactions. It illustrates how the biology underlying GO:0070489 can be repurposed for therapeutic benefit in hematologic malignancies.
From T cell aggregation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate adhesion gene required for homotypic T cell aggregation? | CRISPR knockout in Jurkat or primary T cells followed by aggregation assay |
| Does a specific point mutation in an integrin alter aggregation avidity? | Point-mutation knock-in via CRISPR in T cell lines |
| Can a tagged adhesion receptor be tracked during cluster formation? | Tagged knock-in of fluorescent protein at the endogenous locus |
| Does overexpression of a co-stimulatory receptor enhance aggregation? | CRISPR-mediated overexpression or lentiviral overexpression |
| Which genes regulate T cell aggregation in a genome-wide manner? | CRISPR library screening with aggregation-based selection |
| Can engineered aggregation improve CAR T function? | Ferritin aggregation cell engager and CAR T co-culture models |
How to Study the T cell aggregation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Light microscopy aggregation assay | Formation of T cell clusters over time | Screening chemical or genetic modifiers of aggregation |
| Flow cytometry | Surface adhesion molecule expression and cluster frequency | Phenotyping CRISPR-edited T cells |
| Spatial transcriptomics | Lymphocyte-aggregated regions in tumor tissue | Mapping T cell aggregation in cancer |
| T cell repertoire annotation | Clonal specificity and diversity | Linking aggregation to clonal identity |
| Co-culture with microglia | T cell infiltration and aggregation in neuroinflammation | Tauopathy neurodegeneration models |
| Bispecific antibody aggregation assay | Target-independent T cell activation | Biotherapeutic safety assessment |
| CAR T avidity assay | Engineered aggregation-enhanced T cell function | Leukemia immunotherapy development |
Microscopy-based aggregation assays
Homotypic aggregation can be quantified by light microscopy or confocal imaging of T cell suspensions, where cluster formation is scored over time. This method directly visualizes the process defined by GO:0070489 and is suitable for comparing wild-type and CRISPR-edited T cells.
Flow cytometry for cluster and surface marker analysis
Flow cytometry can measure aggregation-associated changes in surface adhesion molecule expression and identify clustered versus single cells. It is commonly combined with viability dyes and activation markers to distinguish aggregation from cell death.
Spatial transcriptomics and tumor atlas analysis
Spatially resolved atlases of gastric cancer have identified lymphocyte-aggregated regions, providing a template for mapping T cell aggregation in situ. These methods link GO:0070489 to tissue-level immune architecture and can be combined with repertoire annotation [3,5].
Quantitative repertoire annotation
Quantitative annotations of T cell repertoire specificity provide computational tools to characterize the clonal composition of aggregated T cell populations. This approach complements imaging and flow-based aggregation assays by adding specificity information.
How CRISPR Can Be Used to Study GO:0070489 T cell aggregation
Knockout
CRISPR knockout of candidate adhesion molecules such as ITGAL, ITGB2, or CD2 in T cell lines and primary T cells can test whether these genes are required for homotypic aggregation. Loss-of-function models are essential for establishing causality in GO:0070489 and can be paired with aggregation assays for quantitative readouts.
Point Mutation
Point-mutation knock-in can be used to dissect specific residues in adhesion receptors or signaling kinases that control aggregation. For example, mutations affecting CD28/CTLA-4 receptor aggregation or integrin activation can be introduced to test structure-function relationships. Such models provide allele-specific insight beyond simple knockout.
Knock-in
Tagged knock-in of fluorescent proteins at endogenous loci enables real-time tracking of adhesion receptors during cluster formation. Knock-in reporters can also be used to monitor activation-induced changes in gene expression that accompany aggregation.
Overexpression
CRISPR-mediated overexpression or lentiviral overexpression of co-stimulatory receptors or adhesion molecules can enhance aggregation and test sufficiency. Overexpression models are useful for engineering T cells with altered aggregation properties for therapeutic applications.
How EDITGENE Supports T cell aggregation Research
Researchers studying T cell aggregation-related genes often need to determine whether a candidate gene is causally involved in homotypic adhesion, whether a specific residue controls receptor clustering, or whether engineered aggregation can enhance therapeutic T cell function. Answering these questions requires precise, reproducible genome editing models that preserve endogenous regulation while allowing controlled perturbation. EDITGENE provides end-to-end CRISPR services tailored to T cell aggregation research, from knockout and point-mutation models to knock-in reporters, overexpression lines, and library screening with bioinformatics support.
Contact EDITGENE today to design your custom CRISPR model for T cell aggregation research.
Frequently Asked Questions About T cell aggregation
What is T cell aggregation (GO:0070489)?
T cell aggregation is the biological process in which one T cell adheres to one or more other T cells via adhesion molecules, as defined by GO:0070489.
What genes are involved in T cell aggregation?
Genes encoding adhesion molecules and co-stimulatory receptors such as CD28, CTLA-4, ITGAL, ITGB2, CD2, and CD58, as well as signaling and cytoskeletal regulators, are involved in T cell aggregation [4,6].
How is T cell aggregation measured experimentally?
It is commonly measured by microscopy-based cluster formation assays and flow cytometry in T cell suspensions.
Why is T cell aggregation important in cancer?
Lymphocyte-aggregated regions and tertiary lymphoid structures in tumors are linked to cancer immunity and are being mapped in spatially resolved atlases [3,8].
Is T cell aggregation involved in neurodegeneration?
Yes, microglia-mediated T cell infiltration and aggregation drive neurodegeneration in tauopathy models.
Can T cell aggregation be harmful in immunotherapy?
Aggregates of T cell-redirecting bispecific antibodies can cause target-independent immune-cell activation, which is a safety concern.
Can T cell aggregation be engineered for therapy?
Ferritin aggregation cell engagers have been developed to enhance CAR T avidity against refractory leukemias.
What is the difference between T cell aggregation and T cell activation?
T cell aggregation is a cell-cell adhesion process defined by GO:0070489, whereas T cell activation is a broader signaling and functional state; aggregation is often a downstream consequence of activation [4,6].
Which CRISPR models are suitable for studying T cell aggregation?
Knockout, point-mutation knock-in, tagged knock-in, and overexpression models in T cell lines or primary T cells are all suitable, depending on the research question [4,6].
How can I study T cell aggregation in my lab?
You can combine aggregation assays with CRISPR-edited T cell models and, where relevant, spatial transcriptomics or repertoire annotation to link GO:0070489 to disease biology [3,5,6].
Conclusion
GO:0070489 T cell aggregation is a well-defined biological process describing homotypic T cell adhesion via adhesion molecules. Its relevance spans basic immunology, cancer immunity, neurodegeneration, and biotherapeutic engineering, with experimental evidence linking aggregation to tauopathy pathology, lymphocyte-aggregated tumor regions, bispecific antibody safety, and engineered CAR T avidity [1,2,3,7,8]. Researchers can now study this process with a mature toolkit of aggregation assays, flow cytometry, spatial transcriptomics, and CRISPR-based genome editing [3,5,6]. By combining precise CRISPR models with quantitative readouts, it is possible to move from correlation to causation in T cell aggregation research. EDITGENE supports this effort with knockout, point-mutation, knock-in, overexpression, and library screening services tailored to GO:0070489 and its associated genes [4,5,6].
References
- 1. Chen X et al.. 2023. Microglia-mediated T cell infiltration drives neurodegeneration in tauopathy.. Nature 615(7953):668-677 PMID: 36890231
- 2. Li F et al.. 2026. Ferritin aggregation cell engager for CAR T avidity engineering against refractory leukemias.. Cell 189(7):1942-1956.e26 PMID: 41806835
- 3. Gao S et al.. 2026. A spatially resolved atlas of gastric cancer characterises a lymphocyte-aggregated region.. Nat Commun 17(1) PMID: 41593079
- 4. Linsley PS et al.. 1995. CD28/CTLA-4 receptor structure, binding stoichiometry and aggregation during T-cell activation.. Res Immunol 146(3):130-40 PMID: 8525042
- 5. Luo J et al.. 2023. Quantitative annotations of T-Cell repertoire specificity.. Brief Bioinform 24(3) PMID: 37150761
- 6. Hoffman N et al.. 2006. Bifenthrin activates homotypic aggregation in human T-cell lines.. Med Sci Monit 12(3):BR87-94 PMID: 16501417
- 7. Tada M et al.. 2023. Target-independent Immune-cell Activation by Aggregates of T Cell-redirecting Bispecific Antibodies.. J Pharm Sci 112(9):2419-2426 PMID: 37392901
- 8. Lin WP et al.. 2024. T cell exhaustion initiates tertiary lymphoid structures and turbocharges cancer-immunity cycle.. EBioMedicine 104:105154 PMID: 38749300
